Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Study Overview
=================
Brief Summary
-----------------
This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.

Detailed Description
-----------------
PRIMARY OBJECTIVE: I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma. SECONDARY OBJECTIVES: I. To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced refractory cancers/lymphomas/multiple myeloma. II. To evaluate time until death or disease progression. III. To identify potential predictive biomarkers beyond the genomic alteration by which treatment is assigned or resistance mechanisms using additional genomic, ribonucleic acid (RNA), protein and imaging-based assessment platforms. IV. To assess whether radiomic phenotypes obtained from pre-treatment imaging and changes from pre- through post-therapy imaging can predict objective response and progression free survival and to evaluate the association between pre-treatment radiomic phenotypes and targeted gene mutation patterns of tumor biopsy specimens. OUTLINE: STEP 0 (Screening): Patients undergo biopsy along with molecular characterization of the biopsy material for specific, pre-defined mutations, amplifications, or translocations of interest via tumor sequencing and immunohistochemistry. Consenting patients also undergo collection of blood samples for research purposes. STEPS 1, 3, 5, 7 (Treatment): Patients are assigned to 1 of 38 treatment subprotocols based on molecularly-defined subgroup. (See Arms Section) STEPS 2, 4, 6 (Screening): Patients experiencing disease progression on the prior Step treatment or who could not tolerate the assigned treatment undergo review of their previous biopsy results to determine if another treatment is available or undergo another biopsy. Patients may have a maximum of 2 screening biopsies and 2 treatments per biopsy. STEP 8 (Optional Research): Consenting patients undergo end-of-treatment biopsy and collection of blood samples for research purposes. After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 1 year.

Official Title
-----------------
Molecular Analysis for Therapy Choice (MATCH)

Conditions
-----------------
Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Kidney Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Pancreatic Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Recurrent Uterine Corpus Cancer, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma, Uterine Corpus Cancer

Intervention / Treatment
-----------------
* Drug: Adavosertib
* Drug: Afatinib
* Drug: Afatinib Dimaleate
* Drug: Binimetinib
* Procedure: Biopsy
* Procedure: Biospecimen Collection
* Drug: Capivasertib
* Procedure: Computed Tomography
* Drug: Copanlisib
* Drug: Copanlisib Hydrochloride
* Drug: Crizotinib
* Other: Cytology Specimen Collection Procedure
* Drug: Dabrafenib
* Drug: Dabrafenib Mesylate
* Drug: Dasatinib
* Drug: Defactinib
* Drug: Defactinib Hydrochloride
* Procedure: Echocardiography
* Drug: Erdafitinib
* Drug: Fexagratinib
* Drug: Ipatasertib
* Other: Laboratory Biomarker Analysis
* Drug: Larotrectinib
* Drug: Larotrectinib Sulfate
* Procedure: Magnetic Resonance Imaging
* Biological: Nivolumab
* Drug: Osimertinib
* Drug: Palbociclib
* Biological: Pertuzumab
* Drug: PI3K-beta Inhibitor GSK2636771
* Procedure: Radiologic Examination
* Biological: Relatlimab
* Drug: Sapanisertib
* Drug: Sunitinib Malate
* Drug: Taselisib
* Drug: Trametinib
* Biological: Trastuzumab
* Biological: Trastuzumab Emtansine
* Drug: Ulixertinib
* Drug: Vismodegib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ELIGIBILITY CRITERIA FOR SCREENING BIOPSY (STEP 0) Patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to registration; patients that are pregnant or breast feeding are excluded; a patient of childbearing potential is anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: Has achieved menarche at some point Has not undergone a hysterectomy or bilateral oophorectomy; or Has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse prior to study entry, for the duration of study participation, and for 4 months after completion of study; should a patient or partner of the patient become pregnant or suspect a pregnancy while participating in this study, the treating physician should be informed immediately Patients must have histologically documented solid tumors or histologically confirmed diagnosis of lymphoma or multiple myeloma requiring therapy and meet one of the following criteria: Patients must have progressed following at least one line of standard systemic therapy and there must not be other approval/standard therapy available that has been shown to prolong overall survival (i.e. in a randomized trial against another standard treatment or by comparison to historical controls); patients who cannot receive other standard therapy that has been shown to prolong overall survival due to medical issues will be eligible, if other eligibility criteria are met; if the patient is currently receiving therapy, the clinician must have assessed that the current therapy is no longer benefitting the patient prior to enrolling on MATCH, regardless of whether it is considered standard OR Patients for whose disease no standard treatment exists that has been shown to prolong overall survival NOTE: No other prior malignancy is allowed except for the following: Adequately treated basal cell or squamous cell skin cancer In situ cervical cancer Adequately treated stage I or II cancer from which the patient is currently in complete remission Any other cancer from which the patient has been disease-free for 5 years Patients must have measurable disease Patients must meet the criteria below Tumor tissue for the confirmation of rare variant by the MATCH assay is to be submitted, preferably from the same time of collection as that used to determine patient candidacy for treatment arm assignment Registration to Step 0 must occur after stopping prior systemic anti-cancer therapy. There is no specific duration for which patients must be off treatment prior to registration to Step 0, as long as all eligibility criteria are met Patients may have received other non-targeted, immunotherapy or targeted treatment between the prior genetic testing at the outside lab and registration to Step 0. The decision to stop such treatment in favor of participation in MATCH, if no further clinical benefit is expected, is per the treating physician's discretion. Documentation of a lack of response to the prior treatment is not required in these cases Patients with an applicable rare variant must be able to meet the eligibility criteria for the appropriate subprotocols within 4 weeks following notification of treatment assignment Patient meets one of the following criteria: Patient is a candidate for Z1M based on local CLIA assessment of MMRd by immunohistochemistry (IHC) or MSI status by polymerase chain reaction (PCR), adequate tumor tissue is available for submission for mandatory central screening IHC and the patient will be able to meet the eligibility criteria for Z1M within 4 weeks following notification of treatment assignment OR The sites have received results from one of the designated outside laboratories indicating a rare variant that is an actionable Mutation of Interest (aMOI) for specific select subprotocols NOTE: There is no particular window of time after receiving the sequencing report notification of potential eligibility from an outside lab in which the patient must be registered to Step 0, but treatment slots will be assigned on a first come, first serve basis to those who do register to Step 0, and are not held for those notified of potential eligibility who do not register to Step 0 NOTE: Treatment assignment (and the start of the associated deadline for Step 1 registration) may occur shortly after Step 0 registration. Note that certain rare variant arms require submission of archival tissue for central IHC testing to determine treatment assignment. For those arms, adequate tissue for the central IHC is required to be available for submission NOTE: Other potential aMOIs that would be eligibility criteria for NON RARE arms, as determined by the designated laboratories, are not applicable for this process in MATCH Patients must have Eastern Cooperative Oncology Group (ECOG) performance status =< 1 and a life expectancy of at least 3 months Patients must be able to swallow tablets or capsules; a patient with any gastrointestinal disease that would impair ability to swallow, retain, or absorb drug is not eligible Patients who are human immunodeficiency virus (HIV)-positive are eligible if: CD4+ cell count greater or equal to 250 cells/mm^3 If patient is on antiretroviral therapy, there must be minimal interactions or overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment; for experimental cancer therapeutics with CYP3A/4 interactions, protease inhibitor therapy is disallowed; suggested regimens to replace protease inhibitor therapy include dolutegravir given with tenofovir/emtricitabine; raltegravir given with tenofovir and emtricitabine; once daily combinations that use pharmacologic boosters may not be used No history of non-malignancy acquired immune deficiency syndrome (AIDS)-defining conditions other than historical low CD4+ cell counts Probable long-term survival with HIV if cancer were not present Any prior therapy, radiotherapy (except palliative radiation therapy of 30 gray [Gy] or less), or major surgery must have been completed >= 4 weeks prior to start of treatment; all adverse events due to prior therapy have resolved to a grade 1 or better (except alopecia and lymphopenia) by start of treatment; palliative radiation therapy must have been completed at least 2 weeks prior to start of treatment; the radiotherapy must not be to a lesion that is included as measurable disease NOTE: Prostate cancer patients may continue their luteinizing hormone-releasing hormone (LHRH) agonist NOTE: For patients entering the study via the original screening process, patients may receive non-protocol treatment after biopsy (if clinically indicated) until they receive notification of results; however, lack of response must be documented prior to registration to Step 1; new non-protocol treatment will NOT be permitted as intervening therapy after registration to Step 0; the only intervening treatment permitted is prior therapy that the patient already received prior to Step 0 registration; the decision to stop the intervening non-protocol treatment will be left up to the treating physician if patient has an aMOI; however, patients will need to be off such therapy for at least 4 weeks before receiving any MATCH protocol treatment NOTE: For patients entering the study via a designated outside laboratory, no intervening systemic non-protocol treatment is permitted after Step 0 registration; all other eligibility requirements still apply to these patients, including the washouts for prior therapy noted above in this section, the time restrictions outlined, and the eligibility criteria for the intended subprotocol Patients with brain metastases or primary brain tumors must have completed treatment, surgery or radiation therapy >= 4 weeks prior to start of treatment Patients must have discontinued steroids >= 1 week prior to registration to Step 0 and remain off steroids thereafter, except as permitted; patients with glioblastoma (GBM) must have been on stable dose of steroids, or be off steroids, for one week prior to registration to treatment (Step 1, 3, 5, 7) NOTE: The following steroids are permitted (low dose steroid use is defined as prednisone 10 mg daily or less, or bioequivalent dose of other corticosteroid): Temporary steroid use: e.g. for computed tomography (CT) imaging in setting of contrast allergy Low dose steroid use for appetite Chronic inhaled steroid use Steroid injections for joint disease Stable dose of replacement steroid for adrenal insufficiency or low doses for non-malignant disease Topical steroid Steroids required to manage toxicity related to study treatment, as described in the subprotocols Steroids required as pre- or post-chemotherapy medication for acceptable intervening chemotherapy NOTE: Steroids must be completed alongside last dose of chemotherapy Leukocytes >= 3,000/mcL (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration) Absolute neutrophil count (ANC) >= 1,500/mcL (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration) Platelets >= 100,000/mcL (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration) NOTE: Patients with documented bone marrow involvement by lymphoma are not required to meet the above hematologic parameters, but must have a platelet count of at least 75,000/mcL and neutrophil count of at least 1,000/mcL Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (unless documented Gilbert's syndrome, for which bilirubin =< 3 x institutional ULN is permitted) (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration) Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN (up to 5 times ULN in presence of liver metastases) (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration) Creatinine clearance >= 45 mL/min/1.73 m^2 for patients with creatinine levels above institutional ULN As defined by the Cockcroft-Gault equation (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration) Patients must have an electrocardiogram (ECG) within 8 weeks prior to registration to screening step and must meet the following cardiac criteria: Resting corrected QT interval (QTc) =< 480 msec NOTE: If the first recorded QTc exceeds 480 msec, two additional, consecutive ECGs are required and must result in a mean resting QTc =< 480 msec; it is recommended that there are 10-minute (+/- 5 minutes) breaks between the ECGs The following only need to be assessed if the mean QTc > 480 msec Check potassium and magnesium serum levels Correct any identified hypokalemia and/or hypomagnesemia and may repeat ECG to confirm exclusion of patient due to QTc For patients with heart rate (HR) 60-100 beats per minute (bpm), no manual read of QTc is required For patients with baseline HR < 60 or > 100 bpm, manual read of QT by trained personnel is required, with Fridericia correction applied to determine QTc Patient must not have hypokalemia (value < institutional lower limit of normal) No factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval NOTE: Patient must be taken off prohibited medication prior to registration to the screening step (Step 0, 2, 4, 6) and remain off these medications thereafter, unless permitted on a subprotocol for the management of treatment related toxicity; patient must be off the drug for at least 5 half-lives prior to registration to the treatment step (Step 1, 3, 5, 7); the medication half-life can be found in the package insert for Food and Drug Administration (FDA) approved drugs ELIGIBILITY CRITERIA FOR FIRST TREATMENT (STEP 1) NOTE: For patients entering step 0 with assay results from outside laboratories, no systemic treatment is allowed after step 0 registration As MATCH is designed to add additional subprotocols, implement limited expansions of accrual for certain subprotocols, and/or amend existing arm-specific eligibility criteria, some patients entering under the original screening method may be eligible to have their results rerun in MATCHbox, even if they did not match to a treatment initially or did not receive a treatment assignment due to a lack of available assignment slots; patients whose sequence results will be rerun through MATCHbox must also meet the following criteria: Samples must have been collected within 5 months of the activation of the addendum, as there is an additional month needed to get the patients on trial Patient has not had treatment within the 5 months that resulted in a PR or better after the performance of the screening assessment Patient must meet eligibility criteria, including performance status 1 or better and life expectancy of at least 3 months Patients must meet the eligibility requirements with the following exceptions: Patients may have received other non-targeted, immunotherapy or targeted treatment, which could be stopped in favor of returning to MATCH, if no response to the interim treatment has occurred and no further benefit is expected from this interim treatment, per the treating physician's discretion; documentation of a lack of response to the interim treatment is not required in these cases; however, the following restrictions apply: Enrollment onto another investigational therapeutic study is not permitted Patient cannot be responding to interim treatment, since the benefit of the MATCH treatment is unknown and may deprive patient of an effective treatment if it were given when a patient is responding to another treatment NOTE: Patients meeting these criteria will NOT be biopsied at this time point; instead, their step 0 results will be re-interrogated to determine if another treatment is available ELIGIBILITY CRITERIA FOR SECOND SCREENING (STEP 2) Patient's disease has progressed on Step 1 treatment or patient could not tolerate assigned treatment NOTE: PATIENTS ENTERING STEP 1 WITH A RARE VARIANT FROM AN OUTSIDE LAB ARE NOT ELIGIBLE FOR STEP 2 No response and progression (or inability to tolerate further treatment) occurred < 6 months from start of step 1 treatment NOTE: Patients meeting these criteria will NOT be biopsied at this time point; instead, their step 0 MATCH assay results will be re-interrogated to determine if another treatment is available upon registration to this study step; it is not necessary to confirm the availability of another potential treatment assignment in advance; only aMOIs detected by the MATCH assay may be used for the determination of eligibility to a relevant subprotocol OR Progression (or inability to tolerate further treatment) occurred after a (1) response OR (2) after >= 6 months from start of step 1 treatment; patient must have tumor amenable to percutaneous biopsy and be willing and able to undergo a tumor biopsy or bone marrow aspirate for collection and submission of tumor tissue OR patient will be undergoing a procedure due to medical necessity during which the tissue may be collected for the central determination of the presence of one or more of the specific actionable mutations/amplifications of interest (aMOI); archived specimens cannot be accepted Patients must meet eligibility criteria as defined in step 0 ELIGIBILITY CRITERIA FOR SECOND TREATMENT (STEP 3) NOTE: If screening biopsy samples were submitted during step 2, patients may receive non-protocol treatment after biopsy (if clinically indicated) until they receive notification of results however, lack of response must be documented prior to registration to step 3; new non-protocol treatment will NOT be permitted as intervening therapy after registration to step 2; the decision to stop the intervening nonprotocol treatment will be left up to the treating physician if patient has an aMOI; waiting periods as described will apply ELIGIBILITY CRITERIA FOR THIRD SCREENING (STEP 4) Patient's disease has progressed on step 3 treatment or patient could not tolerate assigned treatment Patient must meet one of the following criteria: No response and progression (or inability to tolerate further treatment) occurred < 6 months from start of step 3 (second) treatment AND a biopsy was performed at step 2 screening NOTE: Patients meeting these criteria will NOT be biopsied at this time point; instead, their latest MATCH assay results will be re-interrogated to determine if another treatment is available upon registration to this study step; it is not necessary to confirm the availability of another potential treatment assignment in advance OR Progression (or inability to tolerate further treatment) occurred on step 3 treatment and a biopsy was not performed at step 2 screening (due to presence of additional aMOIs at that stage); patient must have tumor amenable to percutaneous biopsy and be willing and able to undergo a tumor biopsy or bone marrow aspiration for collection and submission of tumor tissue OR patient will be undergoing a procedure due to medical necessity during which the tissue may be collected for the central determination of the presence of one or more of the specific actionable mutations/amplifications of interest; biopsy must not be considered to be more than minimal risk to the patient; archived specimens cannot be accepted Patients must meet eligibility criteria as defined in step 0 NOTE: A patient may have a maximum of 2 screening biopsies (not including re-biopsy due to assay failure), and 2 MATCH treatments per biopsy (if > 1 aMOI) ELIGIBILITY CRITERIA FOR THIRD TREATMENT (STEP 5) NOTE: If screening biopsy was submitted on step 4, patients may receive non-protocol treatment after biopsy (if clinically indicated) until they receive notification of results however, lack of response must be documented prior to registration to step 5; new non-protocol treatment will NOT be permitted as intervening therapy after registration to step 4; the therapy cannot be an arm in the MATCH trial; the decision to stop the intervening nonprotocol treatment will be left up to the treating physician if patient has an aMOI; waiting periods as described will apply ELIGIBILITY CRITERIA FOR FOURTH SCREENING (STEP 6) Patient's disease has progressed on step 5 protocol treatment or patient could not tolerate assigned treatment Patient must have had no response, and progression (or inability to tolerate further treatment) occurred < 6 months from start of step 5 treatment AND a biopsy was performed at step 4 screening NOTE: Patients meeting these criteria will NOT be biopsied at this time point; instead, based on their 2nd biopsy, their results will be interrogated to determine if another treatment is available upon registration to this study step; it is not necessary to confirm the av

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Subprotocol A (EGFR activating mutation)<br>Patients with EGFR activating mutation receive afatinib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Drug: Afatinib<br>* Given PO<br>* Other names: BIBW2992;Drug: Afatinib Dimaleate<br>* Given PO<br>* Other names: Gilotrif;Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>|
| Experimental: Subprotocol B (HER2 activating mutation)<br>Patients with HER2 activating mutation receive afatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Drug: Afatinib<br>* Given PO<br>* Other names: BIBW2992;Drug: Afatinib Dimaleate<br>* Given PO<br>* Other names: Gilotrif;Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>|
| Experimental: Subprotocol C1 (MET amplification)<br>Patients with MET amplification receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Drug: Crizotinib<br>* Given PO<br>* Other names: Xalkori;Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>|
| Experimental: Subprotocol C2 (MET exon 14 deletion/mutation)<br>Patients with MET exon 14 deletion or other mutations that disrupt exon 14 receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Drug: Crizotinib<br>* Given PO<br>* Other names: Xalkori;Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>|
| Experimental: Subprotocol E (EGFR T790M or rare activating mutation)<br>Patients with EGFR T790M or rare activating mutation receive osimertinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>Drug: Osimertinib<br>* Given PO<br>* Other names: Mereletinib;|
| Experimental: Subprotocol F (ALK translocation)<br>Patients with ALK translocation receive crizotinib PO twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Drug: Crizotinib<br>* Given PO<br>* Other names: Xalkori;Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>|
| Experimental: Subprotocol G (ROS1 translocation or inversion)<br>Patients with ROS1 translocation or inversion receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Drug: Crizotinib<br>* Given PO<br>* Other names: Xalkori;Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>|
| Experimental: Subprotocol H (BRAF V600E/R/K/D mutation)<br>Patients with BRAF V600E/R/K/D mutation receive dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Drug: Dabrafenib<br>* Given PO<br>* Other names: GSK2118436;Drug: Dabrafenib Mesylate<br>* Given PO<br>* Other names: Tafinlar;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>Drug: Trametinib<br>* Given PO<br>* Other names: MEK Inhibitor GSK1120212;|
| Experimental: Subprotocol I (PIK3CA mutation)<br>Patients with PIK3CA mutation without RAS mutation or PTEN loss receive taselisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>Drug: Taselisib<br>* Given PO<br>* Other names: RO5537381;|
| Experimental: Subprotocol J (HER2 amplification >= 7 copy numbers)<br>Patients receive pertuzumab IV over 30-60 minutes and trastuzumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO at screening and end of treatment, and biopsy and collection of blood samples on trial and at end of treatment. | Procedure: Biopsy<br>* Undergo tumor biopsy<br>* Other names: Bx;Procedure: Biospecimen Collection<br>* Undergo collection of blood samples<br>* Other names: Specimen Collection;Procedure: Echocardiography<br>* Undergo ECHO<br>* Other names: EC;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>Biological: Pertuzumab<br>* Given IV<br>* Other names: TQB2440;Procedure: Radiologic Examination<br>* Undergo radiologic evaluation<br>* Other names: Radiologic Exam;Biological: Trastuzumab<br>* Given IV<br>* Other names: Trazimera;|
| Experimental: Subprotocol K1 (FGFR amplification)<br>Patients with FGFR amplification receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Drug: Erdafitinib<br>* Given PO<br>* Other names: JNJ-42756493;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>|
| Experimental: Subprotocol K2 (FGFR mutation or fusion)<br>Patients with FGFR mutation or fusion receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Drug: Erdafitinib<br>* Given PO<br>* Other names: JNJ-42756493;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>|
| Experimental: Subprotocol L (mTOR mutation)<br>Patients with mTOR mutation receive sapanisertib PO daily on days 1-28. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. | Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>Drug: Sapanisertib<br>* Given PO<br>* Other names: TAK-228;|
| Experimental: Subprotocol M (TSC1 or TSC2 mutation)<br>Patients with TSC1 or TSC2 mutation receive sapanisertib PO daily on days 1-28. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. | Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>Drug: Sapanisertib<br>* Given PO<br>* Other names: TAK-228;|
| Experimental: Subprotocol N (PTEN mutation or deletion and PTEN expression)<br>Patients with PTEN mutation or deletion and PTEN expression receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>Drug: PI3K-beta Inhibitor GSK2636771<br>* Given PO<br>* Other names: GSK2636771;|
| Experimental: Subprotocol P (PTEN loss)<br>Patients with PTEN loss receive PI3K-beta inhibitor GSK2636771 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>Drug: PI3K-beta Inhibitor GSK2636771<br>* Given PO<br>* Other names: GSK2636771;|
| Experimental: Subprotocol Q (HER2 amplification)<br>Patients with HER2 amplification receive trastuzumab emtansine intravenously (IV) over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. | Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>Biological: Trastuzumab<br>* Given IV<br>* Other names: Trazimera;Biological: Trastuzumab Emtansine<br>* Given IV<br>* Other names: Trastuzumab-MCC-DM1 Immunoconjugate;|
| Experimental: Subprotocol R (BRAF fusion or BRAF non-V600 mutation)<br>Patients with BRAF fusion or BRAF non-V600 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>Drug: Trametinib<br>* Given PO<br>* Other names: MEK Inhibitor GSK1120212;|
| Experimental: Subprotocol S1 (NF1 mutation)<br>Patients with NF1 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>Drug: Trametinib<br>* Given PO<br>* Other names: MEK Inhibitor GSK1120212;|
| Experimental: Subprotocol S2 (GNAQ or GNA11 mutation)<br>Patients with GNAQ or GNA11 mutation receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>Drug: Trametinib<br>* Given PO<br>* Other names: MEK Inhibitor GSK1120212;|
| Experimental: Subprotocol T (SMO or PTCH1 mutation)<br>Patients with SMO or PTCH1 mutation receive vismodegib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>Drug: Vismodegib<br>* Given PO<br>* Other names: Hedgehog Antagonist GDC-0449;|
| Experimental: Subprotocol U (NF2 inactivating mutation)<br>Patients with NF2 inactivating mutation receive defactinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Drug: Defactinib<br>* Given PO<br>* Other names: VS-6063;Drug: Defactinib Hydrochloride<br>* Given PO<br>Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>|
| Experimental: Subprotocol V (cKIT exon 9, 11, 13, or 14 mutation)<br>Patients with cKIT exon 9, 11, 13, or 14 mutation receive sunitinib malate PO QD for 4 weeks. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. | Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>Drug: Sunitinib Malate<br>* Given PO<br>* Other names: Sutent;|
| Experimental: Subprotocol W (FGFR pathway aberrations)<br>Patients with FGFR1-3 mutation or translocation receive FGFR Inhibitor AZD4547 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Drug: Fexagratinib<br>* Given PO<br>* Other names: KB-74810;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>|
| Experimental: Subprotocol X (DDR2 S768R, I638F, or L239R mutation)<br>Patients with DDR2 S768R, I638F, or L239R mutation receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Drug: Dasatinib<br>* Given PO<br>* Other names: Sprycel;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>|
| Experimental: Subprotocol Y (Akt mutation)<br>Patients with Akt mutation receive capivasertib PO BID on days 1-4, 8-11, 15-18, and 22-25. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Drug: Capivasertib<br>* Given PO<br>* Other names: Truqap;Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>|
| Experimental: Subprotocol Z1A (NRAS mutation in codon 12, 13, or 61)<br>Patients with NRAS mutation in codon 12, 13, or 61 receive binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Drug: Binimetinib<br>* Given PO<br>* Other names: Mektovi;Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>|
| Experimental: Subprotocol Z1B (CCND1, 2, or 3 amplification with Rb by IHC)<br>Patients with CCND1, 2, or 3 amplification that have tumor Rb expression by IHC receive palbociclib PO QD for 21 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>Drug: Palbociclib<br>* Given PO<br>* Other names: PD-0332991;|
| Experimental: Subprotocol Z1C (CDK4 or CDK6 amplification and Rb protein)<br>Patients with CDK4 or CDK6 amplification and tumor Rb protein receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>Drug: Palbociclib<br>* Given PO<br>* Other names: PD-0332991;|
| Experimental: Subprotocol Z1D (Loss of MLH1 or MSH2 by IHC)<br>Patients with mismatch repair deficiency (loss of MLH1 or MSH2 by IHC) receive nivolumab IV over 30 minutes on days 1 and 15 for 4 cycles and then on day 1 every 28 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>Biological: Nivolumab<br>* Given IV<br>* Other names: Opdivo;|
| Experimental: Subprotocol Z1E (NTRK1, NTRK2 or NTRK3 gene fusion)<br>Patients with NTRK1, NTRK2, or NTRK3 gene fusion receive larotrectinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>Drug: Larotrectinib<br>* Given PO<br>* Other names: LOXO-101;Drug: Larotrectinib Sulfate<br>* Given PO<br>* Other names: Vitrakvi;|
| Experimental: Subprotocol Z1F (PIK3CA mutation)<br>Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo tumor biopsies at screening and end of treatment as well as CT or MRI at baseline and repeated every 2 cycles for the first 26 cycles then every 3 cycles thereafter until progressive disease or start of another MATCH treatment step. | Procedure: Biopsy<br>* Undergo tumor biopsy<br>* Other names: Bx;Procedure: Computed Tomography<br>* Undergo computed tomography (CT)<br>* Other names: tomography;Drug: Copanlisib<br>* Given IV<br>* Other names: PI3K Inhibitor BAY 80-6946;Drug: Copanlisib Hydrochloride<br>* Given IV<br>* Other names: Copanlisib Dihydrochloride;Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Procedure: Magnetic Resonance Imaging<br>* Undergo magnetic resonance imaging (MRI)<br>* Other names: Structural MRI;|
| Experimental: Subprotocol Z1G (PTEN loss)<br>Patients with PTEN loss receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Drug: Copanlisib<br>* Given IV<br>* Other names: PI3K Inhibitor BAY 80-6946;Drug: Copanlisib Hydrochloride<br>* Given IV<br>* Other names: Copanlisib Dihydrochloride;Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>|
| Experimental: Subprotocol Z1H (PTEN mutation)<br>Patients with PTEN mutation receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Drug: Copanlisib<br>* Given IV<br>* Other names: PI3K Inhibitor BAY 80-6946;Drug: Copanlisib Hydrochloride<br>* Given IV<br>* Other names: Copanlisib Dihydrochloride;Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>|
| Experimental: Subprotocol Z1I (BRCA1 or BRCA2 gene mutation)<br>Patients with BRCA1 or BRCA2 gene mutation receive adavosertib PO QD for 5 days for 2 weeks. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. | Drug: Adavosertib<br>* Given PO<br>* Other names: MK1775;Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>|
| Experimental: Subprotocol Z1K (AKT mutation)<br>Patients receive ipatasertib PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Drug: Ipatasertib<br>* Given PO<br>* Other names: RG-7440;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>|
| Experimental: Subprotocol Z1L (BRAF fusion, aberration or non-V600 mutation)<br>Patients with a BRAF non-V600 mutation or BRAF fusion, or another BRAF aberration receive ulixertinib (BVD-523FB) PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>Drug: Ulixertinib<br>* Give PO<br>* Other names: VRT752271;|
| Experimental: Subprotocol Z1M (LAG-3 expression >= 1%)<br>Patients receive nivolumab IV over 30 minutes and relatlimab IV over 30 minutes on day 1.Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. | Other: Cytology Specimen Collection Procedure<br>* Optional correlative studies<br>* Other names: Cytologic Sampling;Other: Laboratory Biomarker Analysis<br>* Undergo molecular analysis<br>Biological: Nivolumab<br>* Given IV<br>* Other names: Opdivo;Biological: Relatlimab<br>* Given IV<br>* Other names: Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Objective response rate | Defined as the percentage of patients whose tumors have a complete or partial response to treatment. Objective response rate is defined consistent with Response Evaluation Criteria in Solid Tumors version 1.1 criteria for solid tumors, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. For each treatment arm, 90% two-sided confidence intervals will be calculated. | Up to 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | Will be evaluated specifically for each drug (or step). Overall survival will be estimated using the Kaplan-Meier method. | From registration onto that step until death, or censored at the date of last contact, assessed up to 3 years | 
| Progression free survival | Progression free survival will be estimated using the Kaplan-Meier method. For each treatment arm, 90% two-sided confidence intervals will be calculated. | From entry onto that step until determination of disease progression or death from any cause, censored at the date of last disease assessment for patients who have not progressed, assessed at 6 months |